===Dexcom (DXCM) reported earnings on Thur 9 Feb 23 (a/h)

 

Dexcom beats by $0.06, reports revs in-line; guides FY23 revs in-line 

• Reports Q4 (Dec) earnings of $0.34 per share, excluding non-recurring items, $0.06 better than the S&P Capital IQ Consensus of $0.28; revenues rose 16.8% year/year to $815.2 mln vs the $814.52 mln S&P Capital IQ Consensus.
• Co issues in-line guidance for FY23, sees FY23 revs of $3.35-3.49 bln vs. $3.46 bln S&P Capital IQ Consensus.

The company makes devices for diabetes patients

The company makes continuous glucose monitors, or CGMs, for patients with diabetes. These body-worn devices keep tabs on blood sugar in real time. During the December quarter, sales increased 17% to $815.2 million. On an organic basis, sales surged 20%. That beat expectations for $810 million in sales.

Now, Dexcom is focusing on a full U.S. launch of its newest CGM, dubbed G7. The Food and Drug Administration cleared G7 for people age 2 and older last year, following the European clearance.

"As we move into 2023, we are very excited to officially bring G7 to the U.S. market and further advance our strategic initiatives to reach millions of additional people that could benefit from Dexcom CGM," Chief Executive Kevin Sayer said in written remarks.